Your browser doesn't support javascript.
Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD.
Li, Qianqian; Zhang, Mengyi; Liang, Ziteng; Zhang, Li; Wu, Xi; Yang, Chaoying; An, Yimeng; Tong, Jincheng; Liu, Shuo; Li, Tao; Cui, Qianqian; Nie, Jianhui; Wu, Jiajing; Huang, Weijin; Wang, Youchun.
  • Li Q; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
  • Zhang M; Jiangsu Recbio Technology Co., Ltd. Taizhou China.
  • Liang Z; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
  • Zhang L; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
  • Wu X; Graduate School of Peking Union Medical College Beijing China.
  • Yang C; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
  • An Y; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
  • Tong J; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
  • Liu S; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
  • Li T; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
  • Cui Q; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
  • Nie J; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
  • Wu J; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
  • Huang W; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
  • Wang Y; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines Institute for Biological Product Control WHO Collaborating Center for Standardization and Evaluation of Biologicals NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research a
MedComm (2020) ; 3(2): e130, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1782644
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, particularly those with multiple mutations in receptor-binding domain (RBD), pose a critical challenge to the efficacy of coronavirus disease 2019 (COVID-19) vaccines and therapeutic neutralizing monoclonal antibodies (mAbs). Omicron sublineages BA.1, BA.2, BA.3, as well as the recent emergence of C.1.2, B.1.630, B.1.640.1, and B.1.640.2, have multiple mutations in RBD and may lead to severe neutralizing antibody evasion. It is urgent to evaluate the antigenic change of the above seven variants against mAbs and sera from guinea pigs immunized with variants of concern (VOCs) (Alpha, Beta, Gamma, Delta, Omicron) and variants of interest (VOIs) (Lambda, Mu) immunogens. Only seven out of the 24 mAbs showed no reduction in neutralizing activity against BA.1, BA.2, and BA.3. However, among these seven mAbs, the neutralization activity of XGv337 and XGv338 against C.1.2, B.1.630, B.1.640.1, and B.1.640.2 were decreased. Therefore, only five neutralizing mAbs showed no significant change against these seven variants. Using VOCs and VOIs as immunogens, we found that the antigenicity of variants could be divided into three clusters, and each cluster showed similar antigenicity to different immunogens. Among them, D614G, B.1.640.1, and B.1.630 formed a cluster, C.1.2 and B.1.640.2 formed a cluster, and BA.1, BA.2, and BA.3 formed a cluster.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Vaccines / Variants Language: English Journal: MedComm (2020) Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Vaccines / Variants Language: English Journal: MedComm (2020) Year: 2022 Document Type: Article